Janux Therapeutics (JANX) Cash & Equivalents (2020 - 2026)

Janux Therapeutics (JANX) has 7 years of Cash & Equivalents data on file, last reported at $51.8 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 29.72% year-over-year to $51.8 million in Q1 2026; TTM through Mar 2026 was $51.8 million, a 29.72% decrease from a year earlier, with the FY2025 full-year figure at $52.3 million, down 87.85% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $51.8 million, down from $52.3 million in the prior quarter.
• Over the last five years, Cash & Equivalents for JANX reached as high as $430.6 million in Q4 2024 and fell as low as $14.7 million in Q2 2024.
• Historically, Cash & Equivalents has averaged $76.1 million across 5 years, with a median of $51.8 million in 2026.
• Across the five-year window, Cash & Equivalents surged 2142.15% in 2024 and sank 87.85% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $51.4 million in 2022, then plunged by 62.66% to $19.2 million in 2023, then jumped by 2142.15% to $430.6 million in 2024, then sank by 87.85% to $52.3 million in 2025, then slipped by 0.97% to $51.8 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $51.8 million in Q1 2026, $52.3 million in Q4 2025, and $48.4 million in Q3 2025.